

Novel Loss-of-Function PCSK9 Variant Is Associated with French-Canadian Family and with Impaired Processing

Clinical Chemistry

57, 1415-1423

DOI: [10.1373/clinchem.2011.165191](https://doi.org/10.1373/clinchem.2011.165191)

Citation Report

#	ARTICLE	IF	CITATIONS
1	PCSK9 inhibition and LDL cholesterol lowering: the biology of an attractive therapeutic target and critical review of the latest clinical trials. <i>Clinical Lipidology</i> , 2012, 7, 621-640.	0.4	16
2	Loss- and Gain-of-function PCSK9 Variants. <i>Journal of Biological Chemistry</i> , 2012, 287, 33745-33755.	3.4	71
3	Proprotein convertase subtilisin/kexin type 9 inhibition. <i>Current Opinion in Lipidology</i> , 2012, 23, 511-517.	2.7	38
4	The PCSK9 decade. <i>Journal of Lipid Research</i> , 2012, 53, 2515-2524.	4.2	355
5	My road to Damascus: how I converted to the prohormone theory and the proprotein convertases. <i>Biochemistry and Cell Biology</i> , 2012, 90, 750-768.	2.0	18
6	The biology and therapeutic targeting of the proprotein convertases. <i>Nature Reviews Drug Discovery</i> , 2012, 11, 367-383.	46.4	647
7	Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations. <i>Lipids in Health and Disease</i> , 2013, 12, 70.	3.0	50
8	The genetic spectrum of familial hypercholesterolemia in Pakistan. <i>Clinica Chimica Acta</i> , 2013, 421, 219-225.	1.1	12
9	Proprotein <scp>C</scp>onvertases <scp>S</scp>ubtilisin/<scp>K</scp>exin <scp>T</scp>ype 9, an enzyme turned escort protein: Hepatic and extra hepatic functions (ç¬¬9ăžă%èç™1/2è1/2æÉé...řâ€”æž`è%æ°řâ€”Eç`/è<ç281/2é...řKi		
10	Regional Distribution and Metabolic Effect of PCSK9 insLEU and R46L Gene Mutations and apoE Genotype. <i>Canadian Journal of Cardiology</i> , 2013, 29, 927-933.	1.7	32
11	Evaluation of Proprotein Convertase Subtilisin/Kexin Type 9: Focus on Potential Clinical and Therapeutic Implications for Lowâ€”Density Lipoprotein Cholesterol Lowering. <i>Pharmacotherapy</i> , 2013, 33, 447-460.	2.6	5
12	Structural and Functional Analysis of the CspB Protease Required for Clostridium Spore Germination. <i>PLoS Pathogens</i> , 2013, 9, e1003165.	4.7	99
13	The promises of PCSK9 inhibition. <i>Current Opinion in Lipidology</i> , 2013, 24, 307-312.	2.7	17
14	PCSK9 inhibitors. <i>Current Opinion in Lipidology</i> , 2013, 24, 251-258.	2.7	39
15	The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol. <i>Drug Design, Development and Therapy</i> , 2013, 7, 1135.	4.3	40
16	Human Serum PCSK9 Is Elevated at Parturition in Comparison to Nonpregnant Subjects While Serum PCSK9 from Umbilical Cord Blood is Lower Compared to Maternal Blood. <i>Isrn Endocrinology</i> , 2013, 2013, 1-8.	2.0	26
17	The Multifaceted Proprotein Convertases: Their Unique, Redundant, Complementary, and Opposite Functions. <i>Journal of Biological Chemistry</i> , 2013, 288, 21473-21481.	3.4	151
18	Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Inhibitors in the Treatment of Hypercholesterolemia and other Pathologies. <i>Current Pharmaceutical Design</i> , 2013, 19, 3161-3172.	1.9	70

#	ARTICLE	IF	CITATIONS
19	Assessing the functional consequence of loss of function variants using electronic medical record and large-scale genomics consortium efforts. <i>Frontiers in Genetics</i> , 2014, 5, 105.	2.3	3
20	The Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Active Site and Cleavage Sequence Differentially Regulate Protein Secretion from Proteolysis. <i>Journal of Biological Chemistry</i> , 2014, 289, 29030-29043.	3.4	31
21	Having excess levels of PCSK9 is not sufficient to induce complex formation between PCSK9 and the LDL receptor. <i>Archives of Biochemistry and Biophysics</i> , 2014, 545, 124-132.	3.0	14
22	PCSK9 gene mutations and low-density lipoprotein cholesterol. <i>Clinica Chimica Acta</i> , 2014, 431, 148-153.	1.1	37
23	PCSK9: From discovery to therapeutic applications. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 58-66.	1.6	83
24	Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs. <i>Current Atherosclerosis Reports</i> , 2014, 16, 439.	4.8	87
25	Quercetinâ€“glucoside increases lowâ€“density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture. <i>FEBS Open Bio</i> , 2014, 4, 755-762.	2.3	58
26	Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies. <i>Cardiovascular Drugs and Therapy</i> , 2014, 28, 281-289.	2.6	86
27	PCSK9. <i>Circulation Research</i> , 2014, 114, 1022-1036.	4.5	495
28	17â€“Estradiol results in a proprotein convertase subtilisin/kexin type 9â€“dependent increase in lowâ€“density lipoprotein receptor levels in human hepatic HuH7 cells. <i>FEBS Journal</i> , 2015, 282, 2682-2696.	4.7	14
29	Stairs instead of elevators at the workplace decreases <sc>PCSK</sc>9 levels in a healthy population. <i>European Journal of Clinical Investigation</i> , 2015, 45, 1017-1024.	3.4	34
30	Potential of PCSK9 as a new target for the management of LDL cholesterol. <i>Research Reports in Clinical Cardiology</i> , 0, , 73.	0.2	6
31	LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153â€“421): Design, synthesis and biochemical evaluation. <i>European Journal of Medicinal Chemistry</i> , 2015, 92, 890-907.	5.5	34
33	Effects of lipoprotein apheresis on PCSK9 levels. <i>Atherosclerosis Supplements</i> , 2015, 18, 180-186.	1.2	20
34	Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition. <i>Circulation</i> , 2015, 132, 1648-1666.	1.6	152
35	PCSK9 and its modulation. <i>Clinica Chimica Acta</i> , 2015, 440, 79-86.	1.1	30
36	PCSK9 inhibition in LDL cholesterol reduction: Genetics and therapeutic implications of very low plasma lipoprotein levels. , 2015, 145, 58-66.		44
37	Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain. <i>PLoS ONE</i> , 2016, 11, e0157230.	2.5	30

#	ARTICLE	IF	CITATIONS
38	PCSK9 Inhibitors. <i>Cardiology in Review</i> , 2016, 24, 141-152.	1.4	10
39	60 YEARS OF POMC: From the prohormone theory to pro-opiomelanocortin and to proprotein convertases (PCSK1 to PCSK9). <i>Journal of Molecular Endocrinology</i> , 2016, 56, T49-T62.	2.5	43
40	PCSK9 as a Biomarker of Cardiovascular Disease. , 2016, , 125-151.		1
41	Point mutations at the catalytic site of PCSK9 inhibit folding, autoprocessing, and interaction with the LDL receptor. <i>Protein Science</i> , 2016, 25, 2018-2027.	7.6	11
42	Determination of cholesterol in blood. Part 3. Review <i>Journal of Chemistry</i> , 2016, 6, 252-329.	1.0	4
43	Fetal gender and gestational age differentially affect PCSK9 levels in intrauterine growth restriction. <i>Lipids in Health and Disease</i> , 2016, 15, 193.	3.0	23
44	Update on the molecular biology of dyslipidemias. <i>Clinica Chimica Acta</i> , 2016, 454, 143-185.	1.1	105
45	PCSK9 as a therapeutic target for cardiovascular disease. <i>Experimental and Therapeutic Medicine</i> , 2017, 13, 810-814.	1.8	15
46	Complexity of mechanisms among human proprotein convertase subtilisin/kexin type 9 variants. <i>Current Opinion in Lipidology</i> , 2017, 28, 161-169.	2.7	57
47	Endoplasmic Reticulum Stress and Ca ²⁺ Depletion Differentially Modulate the Sterol Regulatory Protein PCSK9 to Control Lipid Metabolism. <i>Journal of Biological Chemistry</i> , 2017, 292, 1510-1523.	3.4	31
48	Hypercholesterolemia: The role of PCSK9. <i>Archives of Biochemistry and Biophysics</i> , 2017, 625-626, 39-53.	3.0	45
49	The Proprotein Convertases in Hypercholesterolemia and Cardiovascular Diseases: Emphasis on Proprotein Convertase Subtilisin/Kexin 9. <i>Pharmacological Reviews</i> , 2017, 69, 33-52.	16.0	90
50	Comparing expression and activity of PCSK9 in SPRET/EiJ and C57BL/6J mouse strains shows lack of correlation with plasma cholesterol. <i>Molecular Genetics and Metabolism Reports</i> , 2017, 10, 11-17.	1.1	1
51	The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3452-3460.	3.6	32
52	PCSK9: Regulation and Target for Drug Development for Dyslipidemia. <i>Annual Review of Pharmacology and Toxicology</i> , 2017, 57, 223-244.	9.4	58
53	Mice Fed a High-Cholesterol Diet Supplemented with Quercetin-Glucoside Show Attenuated Hyperlipidemia and Hyperinsulinemia Associated with Differential Regulation of PCSK9 and LDLR in their Liver and Pancreas. <i>Molecular Nutrition and Food Research</i> , 2018, 62, e1700729.	3.3	29
54	The ever-expanding saga of the proprotein convertases and their roles in body homeostasis. <i>Current Opinion in Lipidology</i> , 2018, 29, 144-150.	2.7	30
55	Stepwise processing analyses of the single-turnover PCSK9 protease reveal its substrate sequence specificity and link clinical genotype to lipid phenotype. <i>Journal of Biological Chemistry</i> , 2018, 293, 1875-1886.	3.4	15

#	ARTICLE	IF	CITATIONS
56	Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1027-1038.	1.5	10
57	Loss-of-function PCSK9 mutants evade the unfolded protein response sensor GRP78 and fail to induce endoplasmic reticulum stress when retained. <i>Journal of Biological Chemistry</i> , 2018, 293, 7329-7343.	3.4	29
59	Associations Between Soluble LDLR and Lipoproteins in a White Cohort and the Effect of PCSK9 Loss-of-Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3486-3495.	3.6	14
60	PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1123-1132.	1.5	39
61	Anti-PCSK9 treatment: is ultra-low low-density lipoprotein cholesterol always good?. <i>Cardiovascular Research</i> , 2018, 114, 1595-1604.	3.8	9
62	Malaria severity: Possible influence of the E670G PCSK9 polymorphism: A preliminary case-control study in Malian children. <i>PLoS ONE</i> , 2018, 13, e0192850.	2.5	12
63	Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies. <i>Cardiovascular Research</i> , 2019, 115, 510-518.	3.8	63
64	Diet-induced hepatic steatosis abrogates cell-surface LDLR by inducing de novo PCSK9 expression in mice. <i>Journal of Biological Chemistry</i> , 2019, 294, 9037-9047.	3.4	40
65	Emerging role of proprotein convertase subtilisin/kexin type-9 (PCSK-9) in inflammation and diseases. <i>Toxicology and Applied Pharmacology</i> , 2019, 370, 170-177.	2.8	18
66	Changes in circulating pro-protein convertase subtilisin/kexin type 9 levels “ experimental and clinical approaches with lipid-lowering agents. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 930-949.	1.8	64
67	Proprotein convertase subtilisin/kexin type 9 inhibitors and lipoprotein(a)-mediated risk of atherosclerotic cardiovascular disease. <i>Current Opinion in Lipidology</i> , 2019, 30, 428-437.	2.7	6
68	Non-antibody Approaches to Proprotein Convertase Subtilisin Kexin 9 Inhibition: siRNA, Antisense Oligonucleotides, Adnectins, Vaccination, and New Attempts at Small-Molecule Inhibitors Based on New Discoveries. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 199.	2.4	47
69	Functional analysis of natural <scp>PCSK</scp>9 mutants in modern and archaic humans. <i>FEBS Journal</i> , 2020, 287, 515-528.	4.7	8
70	PCSK9 Variants in Familial Hypercholesterolemia: A Comprehensive Synopsis. <i>Frontiers in Genetics</i> , 2020, 11, 1020.	2.3	29
71	Leveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical Use. <i>Drug Safety</i> , 2020, 43, 567-582.	3.2	9
72	Protease propeptide structures, mechanisms of activation, and functions. <i>Critical Reviews in Biochemistry and Molecular Biology</i> , 2020, 55, 111-165.	5.2	37
73	The loss-of-function PCSK9Q152H variant increases ER chaperones GRP78 and GRP94 and protects against liver injury. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	29
74	Current Evidence and Future Directions of PCSK9 Inhibition. <i>US Cardiology Review</i> , 0, 15, .	0.5	0

#	ARTICLE	IF	CITATIONS
75	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and the risk for neurocognitive adverse events: A systematic review, meta-analysis and meta-regression. International Journal of Cardiology, 2021, 335, 7-14.	1.7	13
76	The emerging landscape of peptide-based inhibitors of PCSK9. Atherosclerosis, 2021, 330, 52-60.	0.8	23
77	PCSK9 as a Biomarker of Cardiovascular Disease. , 2015, , 1-27.		1
78	Proprotein convertase subtilisin/kexin type 9 inhibits hepatitis C virus replication through interacting with NS5A. Journal of General Virology, 2018, 99, 44-61.	2.9	12
79	PCSK9 Prosegment Chimera as Novel Inhibitors of LDLR Degradation. PLoS ONE, 2013, 8, e72113.	2.5	20
80	Potential Link Between Proprotein Convertase Subtilisin/Kexin Type 9 and Alzheimer's Disease. International Journal of Biomedical Investigation, 2018, 1, 1-18.	0.7	4
81	Identification of Novel Proteins Interacting with Proprotein Convertase Subtilisin/Kexin 9. International Journal of Biomedical Investigation, 2020, 3, 1-17.	0.7	5
82	PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD). Advanced Pharmaceutical Bulletin, 2020, 10, 502-511.	1.4	15
83	The Multifaceted Biology of PCSK9. Endocrine Reviews, 2022, 43, 558-582.	20.1	75
84	Statins and PCSK9 Inhibitors: Defining the Correct Patients. , 2015, , 99-117.		1
85	Proprotein Convertase Subtilisin/Kexin Type 9: Functional Role in Lipid Metabolism and Its Therapeutic Inhibition. Contemporary Cardiology, 2021, , 269-294.	0.1	0
86	Shortcomings on genetic testing of Familial hypercholesterolemia (FH) in India: Can we collaborate to establish Indian FH registry?. Indian Heart Journal, 2022, 74, 1-6.	0.5	2
87	The Emerging Roles of Intracellular PCSK9 and Their Implications in Endoplasmic Reticulum Stress and Metabolic Diseases. Metabolites, 2022, 12, 215.	2.9	10
88	ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease. Neurobiology of Aging, 2022, 115, 20-28.	3.1	20
89	The biological relevance of PCSK9: when less is better. Biochemistry and Cell Biology, 2022, 100, 189-198.	2.0	4
90	Inhibitory Antibodies against PCSK9 Reduce Surface CD36 and Mitigate Diet-Induced Renal Lipotoxicity. Kidney360, 2022, 3, 1394-1410.	2.1	10
91	Molecular and cellular biology of PCSK9: impact on glucose homeostasis. Journal of Drug Targeting, 2022, 30, 948-960.	4.4	8
92	Inclisiran: How Widely and When Should We Use It?. Current Atherosclerosis Reports, 2022, 24, 803-811.	4.8	17

#	ARTICLE	IF	CITATIONS
93	Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond. Current Atherosclerosis Reports, 2022, 24, 821-830.	4.8	29
94	A multienzyme S-nitrosylation cascade regulates cholesterol homeostasis. Cell Reports, 2022, 41, 111538.	6.4	7
95	PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity. Cells, 2022, 11, 4132.	4.1	5
96	PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity. Journal of Experimental and Clinical Cancer Research, 2023, 42, .	8.6	8
97	Efficient prime editing in mouse brain, liver and heart with dual AAVs. Nature Biotechnology, 2024, 42, 253-264.	17.5	33
98	Targeting PCSK9 to tackle cardiovascular disease. , 2023, 249, 108480.		6
99	Application of PCSK9 Inhibitors in Lipid Metabolism and Arteriosclerosis. Advances in Clinical Medicine, 2023, 13, 12430-12438.	0.0	0
100	Effect of repeatedly applied cold water immersion on subclinical atherosclerosis, inflammation, fat accumulation and lipid profile parameters of volunteers. Wiener Klinische Wochenschrift, 0, , .	1.9	0
101	Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside. Signal Transduction and Targeted Therapy, 2024, 9, .	17.1	1